Lisdexamfetamine (Elvanse/Vyvanse) Enzymatic Hydrolysis to d-Amphetamine
Lisdexamfetamine is an inactive oral prodrug in which d-amphetamine is covalently linked to l-lysine by a peptide bond, and the prodrug is converted to active d-amphetamine by hydrolysis primarily in blood. [1]
The hydrolysis occurs in the cytosol of human red blood cells (RBCs). [1]
Specific Enzymes and Subcellular Site
Primary enzymatic location
- Human RBC cytosol is the principal site of lisdexamfetamine conversion to d-amphetamine. [1]
Specific enzyme class (experimentally supported)
- The responsible activity is described as aminopeptidase-like / peptidase-mediated hydrolysis in RBC cytosol. [2]
- Pharmacologic inhibition studies support involvement of metallo-aminopeptidase activity for lisdexamfetamine hydrolysis in RBC cytosol. Dove Medical Press (Sharman et al., 2014)
Specific named enzyme protein
- The exact single RBC enzyme identity is described as not definitively established, with the activation mechanism characterized by an aminopeptidase/metallo-aminopeptidase-like peptidase activity rather than a fully enumerated single gene/protein target. [3]
Step-by-Step Hydrolysis Pathway
- Oral absorption of intact lisdexamfetamine occurs from the gastrointestinal tract. [1]
- In RBC cytosol, lisdexamfetamine is hydrolyzed at the lysine–d-amphetamine peptide bond. [1]
- Hydrolysis releases:
- Active d-amphetamine (responsible for pharmacologic activity), and
-
l-lysine as the byproduct. [1]
-
The conversion is characterized as rate-limited by enzymatic hydrolysis, producing gradual appearance of d-amphetamine in plasma rather than immediate receptor exposure. [4]
How the Enzymatic Process Influences Efficacy
Rate-limited, blood-based activation
- Because conversion is enzyme-mediated in blood (RBC cytosol), pharmacologically active d-amphetamine exposure is governed by the rate of enzymatic hydrolysis, not by immediate release of amphetamine from the gastrointestinal tract. [3]
Consistent systemic delivery of active drug
- The RBC cytosolic peptidase mechanism is associated with smooth and consistent systemic delivery of d-amphetamine from the prodrug. [2]
Reduced dependence on GI conditions and formulation-specific release
- Mechanistic characterization supports a prodrug design in which activation occurs after absorption via biochemical release in blood, rather than requiring gradual drug release mechanisms driven by GI dissolution alone. [3]
Capacity of RBCs for conversion
- In vitro data described in prescribing information indicate substantial hydrolysis at reduced hematocrit, supporting high conversion capacity across physiologic RBC levels. [1]
Clinical Implications of the Mechanism
- The therapeutic activity depends on systemic enzymatic conversion to d-amphetamine, so changes in the functional availability of RBC peptidase activity are expected to influence the tempo of d-amphetamine appearance after dosing. [2]
- The drug’s design supports long daily duration of efficacy through gradual enzymatic generation of active d-amphetamine. [2]